Heung Tae Kim

Hyae-Young Kim, Heung Tae Kim, Ji-Youn Han, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Erlotinib Monotherapy for Stage IIIB/IV Non-small Cell Lung Cancer: A Multicenter Trial by the Korean Cancer Study Group

J. Ahn, M. Ahn, Keunchil Park, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first‐line chemotherapy with second‐line crossover in patients with advanced nonsmall cell lung cancer

Hyae-Young Kim, Heung Tae Kim, Dae-Ho Lee, 2008, Cancer.

An indirect comparison of bevacizumab plus cisplatin‐gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first‐line non‐squamous non‐small cell lung cancer in East Asia

M. Ahn, S. Thongprasert, S. Walzer, 2011, Asia-Pacific journal of clinical oncology.

Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?

P. Jänne, C. Ki, J. Ahn, 2008, Clinical Cancer Research.

Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer ?

C. Ki, J. Ahn, M. Ahn, 2008 .

The Efficacy of ZD1839 (Iressa™) in Patients with Advanced Non-small Cell Lung Cancer which has Progressed After Previous Chemotherapy

Yeon-Hee Park, Heung Tae Kim, B. Ryoo, 2004 .

Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma

Hyae-Young Kim, Heung Tae Kim, Ji-Youn Han, 2011, BMC Cancer.

Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial.

H. Groen, A. Chella, M. Ahn, 2013 .

A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer.

Y. Bang, Dong-Wan Kim, D. Heo, 2004, Oncology reports.

Levels of tobacco-specific metabolites among non-smoking lung cancer cases at diagnosis: case-control findings.

Heung Tae Kim, J. S. Lee, Sang-Hyun Hwang, 2013, Asian Pacific journal of cancer prevention : APJCP.

Effect of Accurate Staging Using Positron Emission Tomography on the Outcomes of Prophylactic Cranial Irradiation in Patients With Limited Stage Small‐Cell Lung Cancer

Heung Tae Kim, Ji-Youn Han, J. S. Lee, 2017, Clinical lung cancer.

Photon Versus Proton Beam Therapy for T1–3 Squamous Cell Carcinoma of the Thoracic Esophagus Without Lymph Node Metastasis

Moon Soo Kim, Tae Hyun Kim, Heung Tae Kim, 2021, Frontiers in Oncology.

Clinical evaluation of incadronate in korean patients with malignancy-associated hypercalcemia: An open-label, multicenter study.

Sung-Bae Kim, Joon-Oh Park, Keunchil Park, 2007, Current therapeutic research, clinical and experimental.

Analysis of Treatment Outcomes of Intraventricular Chemotherapy in 105 Patients for Leptomeningeal Carcinomatosis from Non–Small-Cell Lung Cancer

J. Joo, Heung Tae Kim, Ji-Youn Han, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Subcutaneous Intraventricular Reservoirs

J. Joo, Heung Tae Kim, Ji-Youn Han, 2013 .

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.

J. Ahn, M. Ahn, E. Cho, 2019, The Lancet. Oncology.

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study

Sung-Bae Kim, J. Lunceford, M. Shah, 2019, JAMA oncology.

Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations

Heung Tae Kim, Joo‐Hang Kim, Ji-Youn Han, 2014, Cancer.

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

Hyae-Young Kim, J. Ahn, M. Ahn, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ventriculolumbar Perfusion Chemotherapy for the Treatment of Leptomeningeal Carcinomatosis: A Phase I Study With Pharmacokinetic Data

Heung Tae Kim, Ji-Youn Han, J. S. Lee, 2013, American journal of clinical oncology.

Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer.

Heung Tae Kim, J. S. Lee, T. Yun, 2015, Clinical lung cancer.

A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

Heung Tae Kim, Ji-Youn Han, N. Yoo, 2011, Clinical Cancer Research.

A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive‐disease small cell lung cancer

K. Lim, Heung Tae Kim, Ji-Youn Han, 2011, Cancer.

Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive Disease Small Cell Lung Cancer

K. Lim, Heung Tae Kim, Dae-Ho Lee, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations

K. Lim, Heung Tae Kim, K. Yoon, 2011, Journal of Clinical Pathology.

Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy

Heung Tae Kim, Ji-Youn Han, J. S. Lee, 2012, Journal of Cancer Research and Clinical Oncology.

Circulating Cell-Free DNA in Plasma of Never Smokers with Advanced Lung Adenocarcinoma Receiving Gefitinib or Standard Chemotherapy as First-Line Therapy

Hyae-Young Kim, Heung Tae Kim, K. Yoon, 2011, Clinical Cancer Research.

Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase–Low Squamous Cell Lung Cancer

K. Lim, J. Joo, Heung Tae Kim, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

Ceritinib-Induced Organizing Pneumonia in Lung Cancer: A Retrospective Analysis

Hyun-ju Lim, Heung Tae Kim, Ji-Youn Han, 2020, Targeted Oncology.

Clinical significance of heterogeneity in response to retreatment with epidermal growth factor receptor tyrosine kinase inhibitors in patients with lung cancer acquiring secondary resistance to the drug.

K. Lim, Hyae-Young Kim, Heung Tae Kim, 2014, Clinical lung cancer.

Predictive Biomarkers and Personalized Medicine Circulating Cell-Free DNA in Plasma of Never Smokers with Advanced Lung Adenocarcinoma Receiving Gefitinib or Standard Chemotherapy as First-Line Therapy

Hyae-Young Kim, Heung Tae Kim, K. Yoon, 2011 .

Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib

Heung Tae Kim, Ji-Youn Han, Hyojeong Kim, 2013, Journal of Korean medical science.

Phase I/II study of gefitinib (Iressa®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer

Soo Hyun Lee, Heung Tae Kim, Ji-Youn Han, 2015, Cancer Chemotherapy and Pharmacology.

Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung

Hyae-Young Kim, Heung Tae Kim, Ji-Youn Han, 2013, Journal of Neuro-Oncology.

A nomogram to predict brain metastasis as the first relapse in curatively resected non-small cell lung cancer patients.

Moon Soo Kim, Heung Tae Kim, Ji-Youn Han, 2015, Lung cancer.

Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis

Hyae-Young Kim, Heung Tae Kim, Ji-Youn Han, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

Ventriculolumbar perfusion chemotherapy with methotrexate for treating leptomeningeal carcinomatosis: a Phase II Study.

Heung Tae Kim, Ji-Youn Han, J. S. Lee, 2014, The oncologist.

Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study.

Sung-Bae Kim, M. Shah, F. Lordick, 2019, Journal of Clinical Oncology.

Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial.

J. Ahn, M. Ahn, Keunchil Park, 2009, Lung cancer.

Matrix‐assisted laser desorption/ionization mass spectrometry reveals decreased calcylcin expression in small cell lung cancer

Heung Tae Kim, J. Zo, H. Kim, 2012, Pathology international.

A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.

Heung Tae Kim, W. Koom, Ji-Youn Han, 2009, International journal of radiation oncology, biology, physics.

The Role of Gefitinib Treatment for Korean Never-Smokers with Advanced or Metastatic Adenocarcinoma of the Lung: A Prospective Study

Hyae-Young Kim, Heung Tae Kim, Dae-Ho Lee, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Early Prediction of Response to First-Line Therapy Using Integrated 18F-FDG PET/CT for Patients with Advanced/Metastatic Non-small Cell Lung Cancer

Hyae-Young Kim, K. Kang, Heung Tae Kim, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer

Hyae-Young Kim, Heung Tae Kim, Ji-Youn Han, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer.

K. Lim, Hyae-Young Kim, Heung Tae Kim, 2013, Lung cancer.

Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients.

Heung Tae Kim, Dae-Ho Lee, Ji-Youn Han, 2006, Lung cancer.

A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum‐based chemotherapy

Hyae-Young Kim, Heung Tae Kim, Dae-Ho Lee, 2006, Cancer.

Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.

M. Edelman, Chun-Ming Tsai, Heung Tae Kim, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy

Tae Hyun Kim, J. Kim, Heung Tae Kim, 2014, Radiation oncology.